Medline slides as investors weigh FDA warning, fire-related disruption, and upcoming earnings

Medline Inc. (MDLN) is down 4.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be continued pressure from Medline’s recent FDA warning letter and the operational overhang tied to the June fire that destroyed its Tracy, California distribution facility. With second-quarter results scheduled for August 5, this could also reflect investors reducing risk ahead of earnings while the market waits to see whether margins, remediation work, and supply-chain execution improve.

Details:

The FDA posted a warning letter on May 28 tied to a 2025 inspection of a Medline drug manufacturing site in Waukegan, Illinois, citing quality-system and contamination-investigation shortcomings.

Medline said on July 6 that it leased more than 1.6 million square feet of replacement distribution space after the June 11 Tracy warehouse fire, indicating the incident was large enough to require a major network response.

Management previously said first-quarter 2026 net sales rose to $7.4 billion, but net income fell 25.8% and adjusted EBITDA declined 10.6%, leaving investors sensitive to any sign of further margin pressure.

There is no clear new company-specific negative announcement today, so part of the move may be ongoing sentiment pressure from the May secondary stock sale by existing shareholders and caution ahead of the next earnings report.

Sources:

FDA, Medline, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MDLN Insider Trading Activity

$MDLN insiders have traded $MDLN stock on the open market 31 times in the past 6 months. Of those trades, 1 have been purchases and 30 have been sales.

Here’s a breakdown of recent trading of $MDLN stock by insiders over the last 6 months:

8 HOLDINGS MOZART MANAGER L.L.C. BCP has made 0 purchases and 8 sales selling 61,170,810 shares for an estimated $2,345,618,751.
MOZART ML-2 HOLDCO L.P. BX has made 0 purchases and 8 sales selling 61,170,810 shares for an estimated $2,345,618,751.
& FRIEDMAN CAPITAL PARTNERS X (PARALLEL), L.P. HELLMAN has made 0 purchases and 8 sales selling 57,999,474 shares for an estimated $2,222,909,857.
GROUP CAYMAN INVESTMENT HOLDINGS, L.P. TC sold 26,105,840 shares for an estimated $1,070,339,440
GROUP INC. CARLYLE sold 26,105,840 shares for an estimated $1,070,339,440
MOZART COINVESTMENT HOLDINGS, L.P. CARLYLE sold 26,105,840 shares for an estimated $1,070,339,440
CIRCLE ML HOLDCO GP, LLC CP sold 26,105,840 shares for an estimated $1,070,339,440
DOUGLAS P GOLWAS (Chief Commercial Officer) has made 0 purchases and 2 sales selling 100,000 shares for an estimated $3,677,115.
JESSI L CORCORAN (Principal Accounting Officer) purchased 5,000 shares for an estimated $170,750

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$MDLN Hedge Fund Activity

We have seen 249 institutional investors add shares of $MDLN stock to their portfolio, and 69 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

H&F CORPORATE INVESTORS X, LTD. removed 13,040,572 shares (-13.1%) from their portfolio in Q1 2026, for an estimated $580,305,454
EGERTON CAPITAL (UK) LLP added 12,105,082 shares (+277.3%) to their portfolio in Q2 2026, for an estimated $477,424,434
FMR LLC added 10,201,987 shares (+38.7%) to their portfolio in Q1 2026, for an estimated $453,988,421
CAPITAL RESEARCH GLOBAL INVESTORS added 8,377,467 shares (+56.7%) to their portfolio in Q1 2026, for an estimated $372,797,281
SURGOCAP PARTNERS LP added 6,075,165 shares (+inf%) to their portfolio in Q1 2026, for an estimated $270,344,842
BLACKROCK, INC. added 5,410,710 shares (+47.0%) to their portfolio in Q1 2026, for an estimated $240,776,595
VIKING GLOBAL INVESTORS LP added 4,474,835 shares (+64.3%) to their portfolio in Q1 2026, for an estimated $199,130,157

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MDLN Analyst Ratings

Wall Street analysts have issued reports on $MDLN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Tigress Financial issued a "Buy" rating on 05/13/2026

To track analyst ratings and price targets for $MDLN, check out Quiver Quantitative's $MDLN forecast page.

$MDLN Price Targets

Multiple analysts have issued price targets for $MDLN recently. We have seen 14 analysts offer price targets for $MDLN in the last 6 months, with a median target of $53.5.

Here are some recent targets:

Eric Coldwell from Baird set a target price of $45.0 on 06/03/2026
Glen Santangelo from Barclays set a target price of $45.0 on 06/01/2026
Navann Ty from BNP Paribas set a target price of $40.0 on 05/14/2026
Ivan Feinseth from Tigress Financial set a target price of $62.0 on 05/13/2026
David Larsen from BTIG set a target price of $55.0 on 05/07/2026
Lee Hambright from Bernstein set a target price of $54.0 on 05/07/2026
Patrick Donnelly from Citigroup set a target price of $55.0 on 05/07/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.